Open AccessEvaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
Author(s) -
Chunlin Chen,
Wenwen Zhang,
Muhammad Bari,
Cristina Almansa,
Mike Baratta,
Maria Rosario
Publication year - 2021
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.685
H-Index - 27
ISSN - 1179-1438
DOI - 10.2147/cpaa.s310609
Subject(s) - itraconazole , pharmacokinetics , medicine , pharmacology , ketoconazole , crossover study , tolerability , domperidone , oral administration , metoclopramide , antagonist , placebo , adverse effect , dopamine , receptor , vomiting , antifungal , alternative medicine , pathology , dermatology
Treatment options for gastroparesis, such as metoclopramide and domperidone, are limited because of safety concerns, which may be exacerbated in the presence of inhibitors of drug metabolism. This study evaluated the effect of itraconazole on the pharmacokinetics, safety, and tolerability of trazpiroben (previously TAK-906), a novel, peripherally selective D 2 /D 3 dopamine receptor antagonist.